ArticleCancers2026
Combined Use of Savi Scout and Magtrace for Non-Palpable Breast Cancer: A Retrospective Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-palpable breast cancer management has become less invasive and more efficient, driven by advances in tumor localization and sentinel lymph node (SLN) identification. Savi Scout, using a radar-based localization system, can be implanted into the tumor before neoadjuvant systemic therapy (NST). Magtrace, a superparamagnetic iron oxide nanoparticle for SLN detection, can be administered preoperatively. This study evaluated combining Savi Scout and Magtrace for breast-conserving surgery and SLN biopsy in non-palpable breast cancer.
methodsPatients who underwent breast-conserving surgery and SLN biopsy for non-palpable breast cancer using Savi Scout and Magtrace between December 2022 and June 2026 at HCA Healthcare London Bridge Hospital were retrospectively identified. Outcomes included successful tumor localization, SLN identification, intraoperative signal detection failure, margin status, re-excision rate and staining.
results72 patients were identified (mean age 52 years, standard deviation ± 10), with a total of 78 breast lesions and 73 SLN biopsies. A total of 27.8% (20/72) underwent neo-adjuvant therapy with Savi Scout in situ. SLNs were identified using Magtrace in 95.9% (70/73) of SLN biopsies, with a mean of 2.7 (standard deviation ± 0.7) SLNs identified per procedure. A total of 78 Savi Scout devices were implanted, one for each lesion. Of these, 97.4% (76/78) were localizable intraoperatively, 100.0% (78/78) were retrieved and none migrated. One patient required re-excision for margin involvement.
conclusionsCombined use of Savi Scout and Magtrace is feasible, demonstrates high technical success, and offers pre-operative imaging flexibility in primary surgery for non-palpable breast cancers and post-NST patients. This study evaluates the combination of Savi Scout and Magtrace and demonstrates a practical approach for simultaneous tumor localization and SLN identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.